Impact of Wisteria floribunda Agglutinin-Positive Mac-2-Binding Protein in Patients with Hepatitis C Virus-Related Compensated Liver Cirrhosis

Int J Mol Sci. 2016 Sep 12;17(9):1500. doi: 10.3390/ijms17091500.

Abstract

We aimed to examine the effect of Wisteria floribunda agglutinin-positive Mac-2-binding protein (WFA⁺-M2BP) level on survival comparing with other laboratory liver fibrosis markers in hepatitis C virus (HCV)-related compensated liver cirrhosis (LC) (n = 165). For assessing prognostic performance of continuous fibrosis markers, we adapted time-dependent receiver operating characteristics (ROC) curves for clinical outcome. In time-dependent ROC analysis, annual area under the ROCs (AUROCs) were plotted. We also calculated the total sum of AUROCs in all time-points (TAAT score) in each fibrosis marker. WFA⁺-M2BP value ranged from 0.66 cutoff index (COI) to 19.95 COI (median value, 5.29 COI). Using ROC analysis for survival, the optimal cutoff point for WFA⁺-M2BP was 6.15 COI (AUROC = 0.79348, sensitivity = 80.0%, specificity = 74.78%). The cumulative five-year survival rate in patients with WFA⁺-M2BP ≥ 6.15 COI (n = 69) was 43.99%, while that in patients with WFA⁺-M2BP < 6.15 COI (n = 96) was 88.40% (p < 0.0001). In the multivariate analysis, absence of hepatocellular carcinoma (p = 0.0008), WFA⁺-M2BP < 6.15 COI (p = 0.0132), achievement of sustained virological response (p < 0.0001) and des-γ-carboxy prothrombin < 41 mAU/mL (p = 0.0018) were significant favorable predictors linked to survival. In time-dependent ROC analysis in all cases, WFA⁺-M2BP had the highest TAAT score among liver fibrosis markers. In conclusion, WFA⁺-M2BP can be a useful predictor in HCV-related compensated LC.

Keywords: Wisteria floribunda agglutinin-positive Mac-2-binding protein (WFA+-M2BP); hepatitis C virus; hepatocellular carcinoma; liver cirrhosis; survival; time-dependent receiver operating characteristics (ROC) analysis.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Antigens, Neoplasm / blood*
  • Antiviral Agents / therapeutic use
  • Biomarkers / blood
  • Female
  • Hepatitis C / drug therapy
  • Hepatitis C / metabolism*
  • Hepatitis C / pathology*
  • Humans
  • Liver Cirrhosis / drug therapy
  • Liver Cirrhosis / metabolism
  • Liver Cirrhosis / pathology*
  • Liver Cirrhosis / virology*
  • Male
  • Membrane Glycoproteins / blood*
  • Middle Aged
  • Plant Lectins
  • Prognosis
  • ROC Curve
  • Receptors, N-Acetylglucosamine
  • Survival Analysis
  • Young Adult

Substances

  • Antigens, Neoplasm
  • Antiviral Agents
  • Biomarkers
  • Membrane Glycoproteins
  • Plant Lectins
  • Receptors, N-Acetylglucosamine
  • TAA90K protein, human
  • wisteria lectin